A Troubleshooting Guide for Topical Drug Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Troubleshooting Guide for Topical Drug Manufacturing
Consider critical process parameters and strategies to optimize the manufacturing process


Pharmaceutical Technology
Volume 36, Issue 11, pp. 46-49

Incorporate QbD


Table I: A design of experiments was conducted to determine how the final viscosity of a formula varied based on the amount of shear and temperature during which the shear is applied. Emulsification rate was held constant at high rpm.Emulsification temperature was held constant at 75–80 C. Emulsification time and the rate of low-shear mixing were varied. The goal was to produce the highest product viscosity; the higher rate of shear yielded the best results.
Implementing a quality-by-design (QbD) approach to developing CPPs has become a necessity. Most notably, a design of experiments (DOE) can be used to gain an understanding of what processing parameters have the greatest impact on the critical quality attributes of the final product. This understanding can be used to implement a chemistry, manufacturing, and controls (CMC) strategy to ensure stability, product performance, and process control in manufacturing a topical drug product. A DOE, for example, was conducted to determine how the final viscosity of a formula varied based on the amount of shear and temperature during which the shear is applied. The goal was to produce the product with the highest viscosity. As shown in Table I, the higher rate of shear yielded the best results.

Use process-control tools

Even though preserved, topical formulations do not require the strict process controls required in sterile manufacturing, topical formulations must still have a well understood and controlled process. Emulsions, for example, can be difficult to process because they are inherently thermodynamically unstable. The use of manufacturing vessels with programmable logic controllers (PLCs) is one tool that can provide more reliable and accurate control of the pressure/temperature and mixing speed and times.

Add ingredients in the optimal phase and order

Generally, topical formulations comprise one or more phases. Emulsions, for example, primarily comprise an aqueous phase and a hydrophobic phase. Adding ingredients in the correct phase contributes to overall stability. For example, some polymers, such as microcrystalline cellulose/sodium carboymethylcellulose, must be dispersed and hydrated prior to adding other ingredients.

Most ingredients have an optimal method of incorporation into a formulation. Preservatives, such as parabens, should be added just prior to emulsification to reduce time in contact with water-soluble surfactants at elevated temperatures. Polymers (e.g., carbomer) and gums (e.g., xanthan) must be added slowly to avoid formation of fish eyes and other partially hydrated, undispersed material. These problems can be avoided by using eductors (e.g., Tri-Blender and Quadro Ytron dispersers) or by preparing a slurry of polymer or gum in a medium of low or no solubility (e.g., glycerin or glycols for certain gums or oils for carbomers). These thickeners act as emulsion stabilizers to keep oils or creams suspended in water and prevent separation. Such thickeners can be shear sensitive, however, so they must be processed with care.

As an example, DPT Labs was tasked with manufacturing a formulation that was a fatty-acid-based emulsion neutralized using an amine. With the amine in the water phase upon emulsification, the product immediately gained viscosity, requiring a higher mixing speed. As the product cooled, the formulation hit a critical temperature in which it rapidly thinned out and began splashing out of the mixing tank. Resequencing the product and adding the amine post-emulsification, however, maintained the quality of the product and eliminated negative effects on the formulation and potential danger to staff.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here